| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/09/2005 | EP1191924A4 Pharmaceutical dosage form for pulsatile delivery of (d-threo)-methylphenidate and a second cns stimulant |
| 02/09/2005 | EP1165054A4 Pharmaceutical dosage form for pulsatile delivery of methylphenidate |
| 02/09/2005 | EP1162982B1 USE OF STABILISED OLIGONUCLEOTIDES FOR PREPARING A MEDICament WITH ANTITUMOUR ACTIVITY |
| 02/09/2005 | EP1124443B1 Solid delivery systems for aroma ingredients |
| 02/09/2005 | EP1111995B1 Topical dermal antimicrobial compositions |
| 02/09/2005 | EP1079813B1 Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
| 02/09/2005 | EP1056860B1 High affinity humanized anti-tag-72 monoclonal antibodies |
| 02/09/2005 | EP1037659A4 Fibrinolytic inhibitor for sealant |
| 02/09/2005 | EP1023440B1 Enteric coated microgranules for stabilizing lactic acid bacteria |
| 02/09/2005 | EP0971705B1 Hormone replacement therapy drug formulations for topical application to the skin |
| 02/09/2005 | EP0957927B1 Medical composition and use thereof for the manufacture of a topical barrier formulation, a uv-radiation absorbing formulation, or an antiviral, antifungal, or antiinflammatory formulation |
| 02/09/2005 | EP0383799B2 Adheson variants |
| 02/09/2005 | CN2676917Y 壳聚糖药膜 Chitosan film with |
| 02/09/2005 | CN1578724A System, method and apparatus for producing dosage forms |
| 02/09/2005 | CN1578677A Improved therapeutic protocols |
| 02/09/2005 | CN1578676A Lox concentration of peroxide for treating or preventing vaginal infections |
| 02/09/2005 | CN1578675A Extended, controlled-release pharmaceutical compositions using charged polymers |
| 02/09/2005 | CN1578670A Use of lactalapoprotein in prevention and treatment of microbial or virus infection |
| 02/09/2005 | CN1578664A Depot formulations of iloperidone and a star polymer |
| 02/09/2005 | CN1578657A Process for the preparation of fast dissolving dosage form |
| 02/09/2005 | CN1578647A Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues |
| 02/09/2005 | CN1578626A Multivesicular emulsion topical delivery systems |
| 02/09/2005 | CN1575848A Emulsifier for highly liquid w/o emulsion |
| 02/09/2005 | CN1575821A Hemostatic devices and methods of making same |
| 02/09/2005 | CN1575817A Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same |
| 02/09/2005 | CN1575792A Method for stablizing protein medicine and its application in microball preparation |
| 02/09/2005 | CN1188704C Method For releasing medicament, all composition therein, its use and reagent box |
| 02/09/2005 | CN1188490C Method for extracting anti-oxidant from plant solid slag through self anaerobic fermentation and produced extract |
| 02/09/2005 | CN1188189C Transdermal patch substrate containing 17-deacetyl norgestimate and use of substrate |
| 02/09/2005 | CN1188172C G-CSF conjugates |
| 02/09/2005 | CN1188171C Method of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby |
| 02/09/2005 | CN1188170C Solution comprising prostaglandins and benzyl alcohol |
| 02/09/2005 | CN1188136C Buffered composition for dialysis |
| 02/09/2005 | CN1188134C Preparation having increased in vivo tolerability |
| 02/09/2005 | CN1188130C Quetiapine granules |
| 02/09/2005 | CN1188122C 新制剂 The new formulation |
| 02/09/2005 | CN1188114C 可食包衣组合物 Edible coating composition |
| 02/09/2005 | CN1188113C Pharmaceutical mixture comprising a combination of a profen and other active compounds |
| 02/09/2005 | CN1188112C Production process of polymerized micelle with injected medicine and polymerized micelle composition |
| 02/09/2005 | CN1188111C Dry powder compositions having improved dispersivity |
| 02/09/2005 | CN1188055C Composition |
| 02/08/2005 | US6852816 Zwitterionic polymers |
| 02/08/2005 | US6852756 Use of pleuromutilin derivatives for transdermal treatment of bacterial diseases |
| 02/08/2005 | US6852755 This invention pertains to nitrogen mustard compounds (Formula (II)) and prodrugs therefor (Formula (I)), methods for their preparation, pharmaceutical compositions comprising such compounds, and the use of such compounds and |
| 02/08/2005 | US6852746 6-((2,2- diphenylethyl)amino)-9-(N-ethyl- beta -D-ribofuranosyluronamide)-N--(2-(N'-(1-(2-pyridyl)-4 -piperidyl)ureido)ethyl)-9H-purine-2-carboxamide |
| 02/08/2005 | US6852729 Macrolides |
| 02/08/2005 | US6852724 Administering a sustained release drug dosage-form including >5.0% by weight ranolazine in no more than two tablets per dose to maintain ranolazine plasma levels at a >850 ng base/mL for >24 hours; methacrylic acid copolymer binder |
| 02/08/2005 | US6852709 Biodegradable particles for use in time release agents and gene therapy |
| 02/08/2005 | US6852708 Use of hyaluronic acid and forms to prevent the narrowing of the vascular walls |
| 02/08/2005 | US6852705 DNA vaccines for farm animals, in particular bovines and porcines |
| 02/08/2005 | US6852670 Method for manufacturing anion-layered double hydroxide intercalation compounds and compounds produced thereby |
| 02/08/2005 | US6852334 Cationic peg-lipids and methods of use |
| 02/08/2005 | US6852314 IFN-β liquid formulations |
| 02/08/2005 | US6852308 Iodinated and/or brominated derivatives of aromatic dihydroxy monomers are prepared and polymerized to form radio-opaque polymers. The monomers may also be copolymerized with other dihydroxy monomers. The iodinated and brominated aromatic |
| 02/08/2005 | CA2314313C Stabilized teriparatide solutions |
| 02/08/2005 | CA2151383C Stabilized medicinal aerosol solution formulation |
| 02/03/2005 | WO2005010481A2 Preparation and use of gold glyconanoparticles |
| 02/03/2005 | WO2005010164A2 Nucleic acid biomaterials and methods of formation and use |
| 02/03/2005 | WO2005010151A2 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| 02/03/2005 | WO2005010141A2 Compositions for purifying and crystallizing molecules of interest |
| 02/03/2005 | WO2005010079A1 Thermosensitive poly (organophosphazenes), preparation method thereof and injectable thermosensitive polyphosphazene hydrogels using the same |
| 02/03/2005 | WO2005010075A2 Method for preparing functionalized polymers from polymer alcohols |
| 02/03/2005 | WO2005010053A1 Aminated complex-type sugar chain derivatives and process for the production thereof |
| 02/03/2005 | WO2005010048A2 Rg1 antibodies and uses thereof |
| 02/03/2005 | WO2005009480A2 Implants containing codrugs |
| 02/03/2005 | WO2005009476A1 Intravascular delivery of non-viral nucleic acid |
| 02/03/2005 | WO2005009473A1 Antifungal aerosol external preparation |
| 02/03/2005 | WO2005009472A2 Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
| 02/03/2005 | WO2005009454A1 Periodontal disease therapeutic and/or preventive composition |
| 02/03/2005 | WO2005009447A1 Single dose fast dissolving azithromycin |
| 02/03/2005 | WO2005009436A1 Dispersible formulation of an anti-inflammatory agent |
| 02/03/2005 | WO2005009426A1 Treatment of heaves |
| 02/03/2005 | WO2005009408A2 Sustained release dosage forms of anesthetics for pain management |
| 02/03/2005 | WO2005009406A1 Topical skin care composition containing refined peanut oil |
| 02/03/2005 | WO2005009394A2 Drug delivery in the nervous system |
| 02/03/2005 | WO2005009369A2 A ca6 antigen-specific cytotoxic conjugate and methods of using the same |
| 02/03/2005 | WO2005009356A2 Method for the preparation of controlled release formulations |
| 02/03/2005 | WO2005009276A2 Microbial cellulose wound dressing |
| 02/03/2005 | WO2004087101A3 Oral formulations of cladribine |
| 02/03/2005 | WO2004078122A3 Invisible patch for active agnet controlled delivery |
| 02/03/2005 | WO2004050849A3 Recombinant immunotoxin and use in treating tumors |
| 02/03/2005 | WO2004045641A3 Antigen-complexes |
| 02/03/2005 | WO2004006860A3 Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells |
| 02/03/2005 | WO2004002416A3 Methods and materials for treating human papillomavirus infections |
| 02/03/2005 | WO2003101461A8 Norethindrone sustained release formulations and methods associated therewith |
| 02/03/2005 | WO2003064606A3 Human monoclonal antibodies to prostate specific membrane antigen (psma) |
| 02/03/2005 | WO2003037248A3 Fibrin nanoparticles and uses thereof |
| 02/03/2005 | US20050027115 Cationic lipid-mediated enhancement of nucleic acid immunization of cats |
| 02/03/2005 | US20050027110 Nontoxic lectin conjugated to therapeutic agent for use in treatment and prevention of nervous system disorders |
| 02/03/2005 | US20050027105 Multimeric proteins for use in the treatment and detection of cell proliferative disorders |
| 02/03/2005 | US20050027070 Method for preparing a biocompatible crosslinked matrix and matrix provided thereby |
| 02/03/2005 | US20050027069 Reacting by crosslinking a first synthetic polymer containing multiple nucleophilic groups such as amino groups, with a second synthetic polymer containing multiple electrophilic groups such as succinimidyl groups to covalently bind them; use to prevent surgical adhesions, coat implants |
| 02/03/2005 | US20050027064 Charge-dynamic polymers and delivery of anionic compounds |
| 02/03/2005 | US20050027019 Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
| 02/03/2005 | US20050027015 Feed containing cysteamine or a salt thereof and a stabilizer such as cyclodextrin; increased milk production in cows |
| 02/03/2005 | US20050026996 A taxane such as paclitaxel or docetaxel joined by a hydrolyzable bond to one or more oligomers having a polyethylene glycol moiety; amphiphilic drug conjugate with improved water solubility without drastic increase in molecular weight |
| 02/03/2005 | US20050026995 anticarcinogenic agents comprising a mixture of taxol, solubilizers, stabilizers and anhydrous ethanol, having superior solubility, stability, bioavailability and side effect reduction |
| 02/03/2005 | US20050026981 Stable oral solid drug composition |
| 02/03/2005 | US20050026971 New effector conjugates, process for their production and their pharmaceutical use |
| 02/03/2005 | US20050026924 Compositions containing alpha-2-adrenergic agonist components |